Clinical Trial Update: Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study [Phase 2]

View source ↗

Summary

Open-label Phase 2 pilot study evaluating topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Tacrolimus topical ointment 0.03% (tacrolimus)

Snippet

Sponsor: Assaf-Harofeh Medical Center | Conditions: Allergic Conjunctivitis | Phase 2 | Status: UNKNOWN